GT
NAMS icon

Glenmede Trust’s NewAmsterdam Pharma NAMS Stock Holding History

Glenmede Trust’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$595K Sell
18,575
-3,640
-16% -$119K ﹤0.01% 898
2025
Q4 		$779K Buy
+22,215
New +$808K ﹤0.01% 798
2025
Q1 		– Sell
-9,965
Closed -$256K – 1421
2024
Q4 		$256K Sell
9,965
-17,455
-64% -$371K ﹤0.01% 1158
2024
Q3 		$455K Buy
27,420
+290
+1% +$5.02K ﹤0.01% 965
2024
Q2 		$521K Buy
27,130
+14,465
+114% +$290K ﹤0.01% 890
2024
Q1 		$300K Buy
+12,665
New +$257K ﹤0.01% 1063

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DFO
Duquesne Family Office New York $2.94B AUM 61.92% 1-Year Est. Return